Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC) - PubMed (original) (raw)
. 2010 Jun 1;126(11):2653-62.
doi: 10.1002/ijc.24948.
Affiliations
- PMID: 19816945
- DOI: 10.1002/ijc.24948
Free article
Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC)
Andrea Albinger-Hegyi et al. Int J Cancer. 2010.
Free article
Abstract
Proteins of the lysyl oxidase (LOX) family are important modulators of the extracellular matrix. However, they have an important role in the tumour development as well as in tumour progression. To evaluate the diagnostic and prognostic value of the LOX protein in oral and oropharyngeal squamous cell carcinoma (OSCC) we performed QRT-PCR and immunohistochemical analysis on two tissue microarrays (622 tissue samples in total). Significantly higher LOX expression was detected in high grade dysplastic oral mucosa as well as in OSCC when compared to normal oral mucosa (P < 0.001). High LOX expression was correlated with clinical TNM stage (P = 0.020), lymph node metastases for the entire cohort (P < 0.001), as well as in the subgroup of small primary tumours (T1/T2, P < 0.001). Moreover, high LOX expression was correlated with poor overall survival (P = 0.004) and disease specific survival (P = 0.037). In a multivariate analysis, high LOX expression was an independent prognostic factor, predicting unfavourable overall survival. In summary, LOX expression is an independent prognostic biomarker and a predictor of lymph node metastasis in OSCC. Moreover, LOX overexpression may be an early phenomenon in the pathogenesis of OSCC and thus an attractive novel target for chemopreventive and therapeutic strategies.
Similar articles
- Expression of lysyl oxidase is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.
Sakai M, Kato H, Sano A, Tanaka N, Inose T, Kimura H, Sohda M, Nakajima M, Kuwano H. Sakai M, et al. Ann Surg Oncol. 2009 Sep;16(9):2494-501. doi: 10.1245/s10434-009-0559-5. Epub 2009 Jun 13. Ann Surg Oncol. 2009. PMID: 19526206 - Association of expression aberrances and genetic polymorphisms of lysyl oxidase with areca-associated oral tumorigenesis.
Shieh TM, Lin SC, Liu CJ, Chang SS, Ku TH, Chang KW. Shieh TM, et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4378-85. doi: 10.1158/1078-0432.CCR-06-2685. Clin Cancer Res. 2007. PMID: 17671119 - Upregulated LOX and increased collagen content associated with aggressive clinicopathological features and unfavorable outcome in oral squamous cell carcinoma.
Yu M, Shen W, Shi X, Wang Q, Zhu L, Xu X, Yu J, Liu L. Yu M, et al. J Cell Biochem. 2019 Sep;120(9):14348-14359. doi: 10.1002/jcb.28669. Epub 2019 May 29. J Cell Biochem. 2019. PMID: 31140650 - Clinicopathological and prognostic value of lysyl oxidase expression in gastric cancer: a systematic review, meta-analysis and bioinformatic analysis.
Jia Z, Gao J, Wang Y, Zhou T, Zhang X, Zu G. Jia Z, et al. Sci Rep. 2022 Oct 6;12(1):16786. doi: 10.1038/s41598-022-21402-1. Sci Rep. 2022. PMID: 36202905 Free PMC article. - The rationale for targeting the LOX family in cancer.
Barker HE, Cox TR, Erler JT. Barker HE, et al. Nat Rev Cancer. 2012 Jul 19;12(8):540-52. doi: 10.1038/nrc3319. Nat Rev Cancer. 2012. PMID: 22810810 Review.
Cited by
- ROS Generation and Antioxidant Defense Systems in Normal and Malignant Cells.
Snezhkina AV, Kudryavtseva AV, Kardymon OL, Savvateeva MV, Melnikova NV, Krasnov GS, Dmitriev AA. Snezhkina AV, et al. Oxid Med Cell Longev. 2019 Aug 5;2019:6175804. doi: 10.1155/2019/6175804. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 31467634 Free PMC article. Review. - Hypoxia, inflammation, and the tumor microenvironment in metastatic disease.
Finger EC, Giaccia AJ. Finger EC, et al. Cancer Metastasis Rev. 2010 Jun;29(2):285-93. doi: 10.1007/s10555-010-9224-5. Cancer Metastasis Rev. 2010. PMID: 20393783 Free PMC article. Review. - Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma.
Sung FL, Cui Y, Hui EP, Li L, Loh TK, Tao Q, Chan AT. Sung FL, et al. Am J Cancer Res. 2014 Nov 19;4(6):789-800. eCollection 2014. Am J Cancer Res. 2014. PMID: 25520868 Free PMC article. - Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer.
Fraga A, Ribeiro R, Coelho A, Vizcaíno JR, Coutinho H, Lopes JM, Príncipe P, Lobato C, Lopes C, Medeiros R. Fraga A, et al. BMC Urol. 2017 Jan 31;17(1):12. doi: 10.1186/s12894-017-0201-y. BMC Urol. 2017. PMID: 28143503 Free PMC article. - LOX+ iCAFs in HNSCC have the potential to predict prognosis and immunotherapy responses revealed by single cell RNA sequencing analysis.
Liu X, Li H, Wang Y, Zhang Q, Liu Y, Liu T. Liu X, et al. Sci Rep. 2025 Feb 27;15(1):7028. doi: 10.1038/s41598-025-91036-6. Sci Rep. 2025. PMID: 40016474 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical